Clinical Scorecard: Assessment of PD-L1 Expression, Mismatch Repair Status, and Survival Rates in Colorectal Cancer: A Retrospective Study from Pakistan
At a Glance
Category
Detail
Condition
Colorectal Cancer
Key Mechanisms
PD-L1 expression and microsatellite instability/mismatch-repair (MSI/MMR) status
Target Population
Patients diagnosed with colorectal carcinoma in Pakistan
Care Setting
Retrospective evaluation in a clinical research context
Key Highlights
71.7% of tumors exhibited PD-L1 expression using a TPS cutoff of ≥1%.
No association found between PD-L1 status and overall survival, disease-free survival, or progression-free survival.
MSI-H/dMMR tumors correlated with high PD-L1 expression.
Older age was associated with increased mortality risk.
PD-L1 should remain a research measure rather than a companion diagnostic.
Guideline-Based Recommendations
Diagnosis
Assess PD-L1 expression using the ZR3 clone for research purposes.
Management
MSI/MMR testing is recommended for selecting immunotherapy in CRC.
Monitoring & Follow-up
Monitor overall survival, disease-free survival, and progression-free survival in CRC patients.
Risks
Older age is a risk factor for increased mortality in CRC patients.
Patient & Prescribing Data
Patients diagnosed with colorectal carcinoma from 2020 to 2023.
MSI/MMR status is the clinically actionable biomarker for CRC immunotherapy.
Clinical Best Practices
Utilize MSI/MMR status for immunotherapy selection.
Interpret PD-L1 positivity rates with caution based on assay-specific behavior.
